JTO Clinical and Research Reports, Nov 2023, Volume 4, Issue 11
Journal | English
Image For Activity Cover
Credit Offered
No Credit Offered
Table of Contents

Original Articles:
  • Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC
  • Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC
  • Clinical Trial and Real-World Outcomes of Patients With Metastatic NSCLC in the Post-Platinum–Based Chemotherapy Failure Setting
  • Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
Case Reports
  • Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report
Brief Reports
  • Effective Communication About Lung Cancer Screening Without Iatrogenic Stigma: A Brief Report Case Study Using the Lung Cancer Stigma Communications Assessment Tool of LungTalk 
  • Real-World Evidence of EGFR Targeted Therapy in NSCLC– A Brief Report of Decade Long Single Center Experience
JTO Clinical and Research Reports is the official open access journal of the International Association for the Study of Lung Cancer. It aims to complement the Journal of Thoracic Oncology by offering authors a gold open access publication option and publishing the following article types in particular:
  • Phase I trials
  • Well performed single-arm phase II trials
  • Subset analyses of published trials
  • Impactful retrospective Studies
  • Database analysis
  • Large institutional series
  • High-quality case reports
  • Region-specific clinical trials
  • Subspecialty thoracic oncology studies
  • Selected high-quality meeting reports
As an open access journal with no subscription charges, JTO CRR requires authors to pay a fee to cover the costs associated with publication. This ensures your article will be immediately and permanently free to access by everyone.
Powered By